[Sinovac Announces Receipt of Competing Non-Binding “Going Private” Proposal The special committee of the Company’s independent directors, which was formed to consider the preliminary non-binding proposal letter, dated January 30, 2016, from Mr. Weidong Yin, chairman, president and chief executive officer of the Company, and SAIF Partners IV L.P. and/or its affiliates will carefully consider and evaluate both proposals with] []
[Sinovac Announces Receipt of Competing Non-Binding “Going Private” Proposal The special committee of the Company’s independent directors, which was formed to consider the preliminary non-binding proposal letter, dated January 30, 2016, from Mr. Weidong Yin, chairman, president and chief executive officer of the Company, and SAIF Partners IV L.P. and/or its affiliates will carefully consider and evaluate both proposals with] []
[Joint Filing Agreement This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument. [Remainder of this page has been left intentionally blank.] SAIF Partners IV L.P. Andrew Y. Yan Director of SAIF IV GP Capital Ltd., which is the General Partner of SAIF IV GP, L.P., which is] [January 30, 2016 The Board of Directors Sinovac Biotech Ltd. No. 39 Shangdi Xi Road, Haidian District, Beijing 100085 People’s Republic of China Dear Members of the Board of Directors Company Buyer Group Proposal Transaction 2 We believe that our Proposal provides a very attractive opportunity to the Company’s shareholders. Our Proposal represents a premium of approximately 23.11% to the] []
[Sinovac Announces Receipt of a Preliminary Non-Binding Proposal to Acquire the Company and Formation of Independent Special Committee The Board has formed a special committee consisting of three independent directors (the "Special Committee"), Mr. Simon Anderson, Mr. Yuk Lam Lo and Mr. Meng Mei, to consider the proposal. Mr. Simon Anderson is appointed as the chairman of the Special Committee.] [FORM 6-K -------------- ---------- SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F ___ SINOVAC BIOTECH LTD. 6-K 1 v430208_6k.htm FORM 6-K]
[Sinovac Biotech Announces Issuance of GMP Certificate for EV71 Vaccine BEIJING, January 28, 2016 - Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today that the China Food and Drug Administration (“CFDA”) has issued the Good Manufacturing Practices (“GMP”) certificate to Sinovac for the Company's Enterovirus 71 ("EV71") vaccine. This marks the completion of the] []
[Sinovac Biotech Announces Issuance of GMP Certificate for EV71 Vaccine BEIJING, January 28, 2016 - Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today that the China Food and Drug Administration (“CFDA”) has issued the Good Manufacturing Practices (“GMP”) certificate to Sinovac for the Company's Enterovirus 71 ("EV71") vaccine. This marks the completion of the] []
[Sinovac Obtains Clinical Trial Approval for Sabin-IPV Candidate BEIJING, December 10, 2015 -- Sinovac Biotech Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that the Company has obtained approval to begin human clinical trials on its Sabin Inactivated Polio Vaccine (or “sIPV”) candidate. In preparation of beginning human clinical trials, Sinovac is currently finalizing the clinical] [Sinovac Obtains New Drug Certificate and Production License for EV71 Vaccine BEIJING, January 4, 2016--Sinovac Biotech Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that the China Food and Drug Administration (CFDA) issued the new drug certificate and production license for its Enterovirus 71 ("EV71") vaccine. As previously announced, the CFDA completed its Good Manufacturing Practices] [FORM 6-K -------------- ---------- SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F ___ SINOVAC BIOTECH LTD. 6-K 1 v428191_6k.htm FORM 6-K]
[Sinovac Obtains Clinical Trial Approval for Sabin-IPV Candidate BEIJING, December 10, 2015 -- Sinovac Biotech Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that the Company has obtained approval to begin human clinical trials on its Sabin Inactivated Polio Vaccine (or “sIPV”) candidate. In preparation of beginning human clinical trials, Sinovac is currently finalizing the clinical] [Sinovac Obtains New Drug Certificate and Production License for EV71 Vaccine BEIJING, January 4, 2016--Sinovac Biotech Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that the China Food and Drug Administration (CFDA) issued the new drug certificate and production license for its Enterovirus 71 ("EV71") vaccine. As previously announced, the CFDA completed its Good Manufacturing Practices] [FORM 6-K -------------- ---------- SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F ___ SINOVAC BIOTECH LTD. 6-K 1 v428191_6k.htm FORM 6-K]
[Sinovac Reports Unaudited Third Quarter Financial Results -- Conference call scheduled for Thursday, November 12, 2015 at 8:00 AM ET -- BEIJING, November 11, 2015 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited third quarter and nine month financial results for the period ended September 30, 2015. Third Quarter] []
[Sinovac Reports Unaudited Third Quarter Financial Results -- Conference call scheduled for Thursday, November 12, 2015 at 8:00 AM ET -- BEIJING, November 11, 2015 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited third quarter and nine month financial results for the period ended September 30, 2015. Third Quarter] []
